AveXis (NASDAQ:AVXS)‘s stock had its “buy” rating reaffirmed by analysts at BMO Capital Markets in a report issued on Thursday. They presently have a $150.00 target price on the stock. BMO Capital Markets’ target price suggests a potential upside of 38.57% from the stock’s current price.
A number of other brokerages have also weighed in on AVXS. Citigroup set a $132.00 target price on shares of AveXis and gave the stock a “buy” rating in a research note on Friday, January 5th. Canaccord Genuity set a $110.00 target price on shares of AveXis and gave the stock a “hold” rating in a research note on Wednesday, December 20th. BidaskClub lowered shares of AveXis from a “hold” rating to a “sell” rating in a research note on Thursday, December 14th. Bank of America reduced their target price on shares of AveXis from $115.00 to $112.00 and set a “buy” rating for the company in a research note on Friday, November 10th. Finally, Credit Suisse Group initiated coverage on shares of AveXis in a research note on Wednesday. They issued an “outperform” rating and a $134.00 target price for the company. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $113.89.
AveXis (NASDAQ:AVXS) traded down $1.92 on Thursday, hitting $108.25. 777,156 shares of the company were exchanged, compared to its average volume of 547,921. AveXis has a 1-year low of $50.56 and a 1-year high of $119.00. The company has a market cap of $3,885.53, a PE ratio of -19.40 and a beta of 2.46.
In other news, VP James J. Litalien sold 5,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $106.52, for a total transaction of $532,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80. Following the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at $180,242.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,340 shares of company stock valued at $5,851,445. Company insiders own 18.60% of the company’s stock.
Several institutional investors have recently bought and sold shares of AVXS. Strs Ohio acquired a new position in shares of AveXis during the 3rd quarter worth about $116,000. Ameritas Investment Partners Inc. boosted its stake in shares of AveXis by 331.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after buying an additional 1,622 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of AveXis by 688.6% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after buying an additional 1,577 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of AveXis during the 3rd quarter worth about $200,000. Finally, Deschutes Portfolio Strategy LLC acquired a new stake in AveXis in the 3rd quarter valued at about $203,000. Institutional investors own 92.88% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/21/avexis-avxs-buy-rating-reiterated-at-bmo-capital-markets.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.